Shares of Sangamo Therapeutics Inc. (SGMO) are currently trading at $10.00, up 30 cents or 3.09% Wednesday morning. The stock has been trading in the range of $4.81 – $13.20 for the past one year, with trading volume of over 315K versus an average volume of 1.62 million shares.
Sangamo Therapeutics and Pfizer Inc. (PFE) announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients.
AFFINE is a global Phase 3, open-label, multicenter, single arm study that will evaluate the efficacy and safety of giroctocogene fitelparvovec in patients with moderately severe to severe hemophilia A.
Source: Read Full Article